Celgene’s Lung Cancer Drug Gets FDA ‘Fast Track’ Approval
September 5th, 2008
Celgene Corp. a pharmaceutical company based in Summit, today announced that its lung cancer drug, “Amrubicin,” has been granted “fast track” approval by the U.S. Food and Drug Administration. Amrubicin is for the treatment of small cell lung cancer after chemotherapy, the company said in a statement.